Amarantus BioScience

Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International bit.ly/2GYvfHw $AMBS

Amarantus Releases Letter to Shareholders bit.ly/2Sf9Mj3 $AMBS

Amarantus Acquires Majority Interest in CBD Wellness Company Hempori bit.ly/38J7lMe $AMBS

Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products bit.ly/2Faqn1k $AMBS

Amarantus Provides Recapitalization Update to Shareholders bit.ly/2XvxtFV $AMBS

Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation bit.ly/2LoFrNh $AMBS

Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association bit.ly/2ZF9MLp $AMBS

Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference bit.ly/2Rt1aoh

$AMBS President & CEO Gerald Commissiong recently presented at the 9th Annual LD Micro Invitational Conference. Listen to a webcast replay here: bit.ly/2RgH8wV

Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics bit.ly/2Zn0aEE $AMBS

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan bit.ly/2sz6ydO $AMBS

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa bit.ly/2FBuUv1 $AMBS

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries bit.ly/2RGjmNG $AMBS

Amarantus Provides 2019 Roadmap bit.ly/2SC6KEp $AMBS

Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0 bit.ly/2SpLtNS

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma bit.ly/2BCPOaR $AMBS

Amarantus Provides Corporate Update bit.ly/2LylWyG

MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology bit.ly/2J7Nx7R

Amarantus Provides Update on Elto Pharma Capital Formation Plan bit.ly/2JmzuMH